Abstract: Pharmaceutical compositions may include chloroquine. More specifically, a pharmaceutical composition comprising chloroquine or pharmaceutically acceptable salt(s) thereof for use in the treatment or prevention of a viral lung infection, preferably caused by Betacoronavirus, including but not limited to 2019-nCoV (coronavirus), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV), wherein the pharmaceutical composition is administered by inhalation. An improved delivery into the lungs of a subject with minimum systemic exposure may be achieved.

Abstract: A pharmaceutical composition may include hydroxychloroquine or a pharmaceutically acceptable salt thereof, and a solvent. The pharmaceutical composition may include 1 to 400 mg/mL hydroxychloroquine or a pharmaceutically acceptable salt thereof, wherein the solvent is selected from propylene glycol, glycerine, propane-1,3-diol and water or combinations thereof and. The pharmaceutical composition may be suitable for thermal aerosolization. A pharmaceutical composition including hydroxychloroquine or a pharmaceutically acceptable salt thereof may be used in the treatment or prevention of a viral lung infection, wherein the pharmaceutical composition is administered by oral inhalation.